Effects of Angiotensin Receptor Neprilysin Inhibitors on Inducibility of Ventricular Arrhythmias in Rats with Ischemic Cardiomyopathy

Huo, Junyu; Jiang, Weimin; Chen, Chu; Chen, Ran; Ge, Tiantian; Chang, Qing; Zhu, Lin; Jiang, Zhixin; Shan, Qijun

doi:10.1536/ihj.19-065

Cited by 10 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clustering analysis based on log likelihood ratio (LLR) revealed a total of 17 clusters with a modularity Q of 0.762 and a mean profile value of 0.8986, showing good homogeneity ( 31 ). They contain a large number of concerns of ARNI research in the cardiovascular field, including drugs [#1 angiotensin II ( 32 ), #3 ivabradine ( 33 ), #4 sacubitril-valsartan ( 34 ), #5 sacubitril/valsartan ( 35 ), #6 angiotensin ( 36 ), #8 angiotensin receptor-neprilysin inhibitor ( 37 ), #9 sacubitril ( 38 )], indications [#2 hypertension ( 39 ), #11 heart failure with preserved ejection fraction ( 40 )], management [#0 management ( 41 )], guidelines [#14 ESC ( 42 )], etiology [#16 etiology ( 43 )], and observables [#7 survival ( 44 ), #10 medication adherence ( 45 ), #12 natriuretic peptide biomarkers ( 46 )] ( Figures 7C,D ). In recent years, due to the emergence of some important new evidence-based medicine for heart failure drugs, the 2021 ESC guidelines ( 47 ) have been updated in this regard, and the status of ARNI has been importantly elevated to become the first-line drug for heart failure treatment, which brings hope for the treatment of heart failure patients.…”

Section: Resultsmentioning

confidence: 99%

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022

Shi

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Cardiovascular disease (CVD) has become a huge challenge for the global public health system due to its high morbidity, mortality and severe economic burden. In recent years, angiotensin receptor neprilysin inhibitor (ARNI), a new class of drugs, has shown good therapeutic effects on CVD patients in several clinical studies, reducing the morbidity and mortality of CVD patients. In this study, we retrieved publications on ARNI research in the cardiovascular field from the Web of Science core collection and analyzed the annual output, spatial and temporal distribution, institutions and authors, core journals, keywords and co-cited literature based on CiteSpace. As a result, 604 publications were retrieved, and the number of annual publications generally increased year by year, with the largest number of articles. The analysis of the co-occurrence of output countries and authors showed that a few developed countries such as the United States, Canada, and United Kingdom are the most active in this field, forming academic groups represented by John Joseph Valentine McMurray and Scott D. Solomon, and New England Journal of Medicine, Cirulation, and Journal of the American College of Cardiology are the most popular journals in the field, with research hotspots focused on ARNI in the treatment of total ejection fraction heart failure, hypertension and its target organ damage, with the potential for future benefit throughout the cardiovascular event chain as research progresses. This study reveals the prospective application of ARNI in the cardiovascular field and the research hotspots, providing broader and deeper guidance for its use in the clinic, which is beneficial to improve the treatment and prognosis of CVD patients.

show abstract

Section: Resultsmentioning

confidence: 99%

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022

Shi

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…As well known, ARNI is commonly used in clinical treatment of heart failure. For instance, its effect on VAs prevention has been widely reported [27,28,29], but not SGLT2i.…”

Section: Discussionmentioning

confidence: 99%

“…ARNI (Novartis Pharma Schweiz AG, Chinese national medicine permission number J20190001) was administered intragastrically at a dose of 68 mg/kg, and Dapa (AstraZeneca Pharmaceuticals LP, Chinese national medicine permission number J20170040) was administered intragastrically at a dose of 3 mg/kg for 4 weeks, respectively. The medication method for ARNI and Dapa was adopted according to previously published literature [15,16,17].…”

Section: Animalsmentioning

confidence: 99%

Cardioprotection of Sodium–Glucose Cotransporter 2 Inhibition in Rats With Isoproterenol-Induced Cardiomyopathy

Wang

Wei

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) has been reported to improve glycaemic control in patients with type 2 diabetes. The aim of this study was to investigate the effect of SGLT2i Dapagliflozin (Dapa) on cardiomyopathy induced by isoproterenol (ISO) and its potential mechanism.Methods: Fifty male Sprague Dawley rats were randomly assigned to Control (n = 10) and ISO (2.5 mg/kg/day)-treated groups (n = 40). After 2 weeks, 28 survived rats with obvious left ventricular dysfunction in ISO group were randomized into three groups for medication including ARNI (angiotensin receptor neprilysin inhibitor, 68 mg/kg/day, n = 9), Dapa (3 mg/kg/day, n = 9) and ISO (saline, n = 10) for 4 weeks. After that, electrical programmed stimulation (EPS) was performed in all groups for the evaluation of the susceptibility of ventricular arrhythmias (VAs). Echocardiography was used to evaluate cardiac function. Results: Echocardiography revealed significant left ventricular (LV) dysfunction in rats with ISO treatment for 2 weeks compared to the control group. Dapa administration for 4 weeks reduced the cumulative risk of death, myocardial fibrosis, plasma angiotensin II level and its functional receptor AT1R protein expression in the heart, and proinflammatory cytokines levels in the cardiac tissue of ISO-treated rats. It also improved cardiac function and inhibited oxidative stress when compared to the ISO group. These effects were similar to ARNI. However, Dapa showed a greater efficacy than ARNI in reducing left ventricular end-diastolic volume, lowing heart rate and VAs, and decreasing body weight and plasma glucose in ISO-treated rats. Conclusion: Dapa effectively improved the myocardial remodelling and oxidative stress like ARNI in ISO-induced cardiomyopathy in rats, but Dapa may be more effectively in decreasing VAs, and improving cardiac function when compared to ARNI. The mechanisms by which Dapa exerts protective effects on cardiomyopathy may be related to its antioxidant capacity and hypoglycemic action.

show abstract

“…In the setting of chronic MI and HF, sacubitril/valsartan-treated rabbits also consistently displayed shorter APD, faster conduction velocity and reduced ventricular arrhythmia inducibility [51,52]. Similarly, in rats with MI-induced HF, sacubitril/valsartan attenuated the HF-induced ventricular ERP prolongation through transcriptional regulation of cardiac potassium channels [53], while in rats with ischemic cardiomyopathy, ARNI lowered ventricular arrhythmia inducibility, attenuated sympathetic neural remodeling, reversed myocardial fibrosis and increased connexin-43 expression [54].…”

Section: Preclinical Studies Investigating the Electrophysiological Consequences Of Arnimentioning

confidence: 96%

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias

Sutanto

Dobrev

Heijman

2021

IJMS

View full text Add to dashboard Cite

The renin-angiotensin-aldosterone system (RAAS) plays a major role in cardiovascular health and disease. Short-term RAAS activation controls water and salt retention and causes vasoconstriction, which are beneficial for maintaining cardiac output in low blood pressure and early stage heart failure. However, prolonged RAAS activation is detrimental, leading to structural remodeling and cardiac dysfunction. Natriuretic peptides (NPs) are activated to counterbalance the effect of RAAS and sympathetic nervous system by facilitating water and salt excretion and causing vasodilation. Neprilysin is a major NP-degrading enzyme that degrades multiple vaso-modulatory substances. Although the inhibition of neprilysin alone is not sufficient to counterbalance RAAS activation in cardiovascular diseases (e.g., hypertension and heart failure), a combination of angiotensin receptor blocker and neprilysin inhibitor (ARNI) was highly effective in several clinical trials and may modulate the risk of atrial and ventricular arrhythmias. This review summarizes the possible link between ARNI and cardiac arrhythmias and discusses potential underlying mechanisms, providing novel insights about the therapeutic role and safety profile of ARNI in the cardiovascular system.

show abstract

Effects of Angiotensin Receptor Neprilysin Inhibitors on Inducibility of Ventricular Arrhythmias in Rats with Ischemic Cardiomyopathy

Cited by 10 publications

References 45 publications

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022

Cardioprotection of Sodium–Glucose Cotransporter 2 Inhibition in Rats With Isoproterenol-Induced Cardiomyopathy

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias

Contact Info

Product

Resources

About